VCL
Basic information
Region (hg38): 10:73995193-74121363
Links
Phenotypes
GenCC
Source:
- hypertrophic cardiomyopathy 15 (Limited), mode of inheritance: AD
- familial isolated dilated cardiomyopathy (Supportive), mode of inheritance: AD
- dilated cardiomyopathy 1W (Limited), mode of inheritance: AD
- hypertrophic cardiomyopathy 15 (Limited), mode of inheritance: AD
- dilated cardiomyopathy 1W (Strong), mode of inheritance: AD
- hypertrophic cardiomyopathy 15 (Limited), mode of inheritance: AD
- hypertrophic cardiomyopathy (Disputed Evidence), mode of inheritance: AD
- dilated cardiomyopathy (Moderate), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Cardiomyopathy, familial hypertrophic 15; Cardiomyopathy, dilated, 1W | AD | Cardiovascular | Surveillance (including with echocardiography, as asymptomatic individuals with variants have been found to have detectable disease prior to clinical presentation), preventive measures, and early medical management may be helpful to help decrease morbidity and mortality related to cardiomyopathy | Cardiovascular | 11815424; 16712796; 16236538 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the VCL gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 260 | 269 | ||||
missense | 598 | 603 | ||||
nonsense | 21 | 22 | ||||
start loss | 0 | |||||
frameshift | 21 | 22 | ||||
inframe indel | 5 | |||||
splice donor/acceptor (+/-2bp) | 15 | 17 | ||||
splice region | 36 | 48 | 1 | 85 | ||
non coding | 39 | 140 | 47 | 226 | ||
Total | 1 | 4 | 703 | 404 | 52 |
Variants in VCL
This is a list of pathogenic ClinVar variants found in the VCL region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
10-73997822-A-G | Benign (Jun 18, 2018) | |||
10-73997944-A-G | Benign (Jun 19, 2018) | |||
10-73998025-C-T | Likely benign (Sep 07, 2019) | |||
10-73998048-G-A | Likely benign (Dec 23, 2018) | |||
10-73998112-C-T | Dilated cardiomyopathy 1W | Uncertain significance (Jan 13, 2018) | ||
10-73998146-T-G | Dilated cardiomyopathy 1W | Uncertain significance (Jan 13, 2018) | ||
10-73998150-G-T | Dilated cardiomyopathy 1W | Uncertain significance (Jan 13, 2018) | ||
10-73998195-G-A | not specified | Likely benign (Oct 28, 2015) | ||
10-73998204-C-T | Cardiovascular phenotype | Uncertain significance (May 25, 2023) | ||
10-73998211-C-G | Dilated cardiomyopathy 1W | Uncertain significance (Aug 25, 2023) | ||
10-73998213-A-C | Dilated cardiomyopathy 1W | Likely benign (Feb 25, 2022) | ||
10-73998215-T-C | not specified | Uncertain significance (Feb 19, 2024) | ||
10-73998221-A-C | Dilated cardiomyopathy 1W | Uncertain significance (Jul 30, 2020) | ||
10-73998225-G-A | Dilated cardiomyopathy 1W | Likely benign (Mar 28, 2020) | ||
10-73998227-G-A | Dilated cardiomyopathy 1W • Cardiovascular phenotype | Uncertain significance (Nov 15, 2022) | ||
10-73998227-G-T | Dilated cardiomyopathy 1W • Dilated cardiomyopathy 1W;Hypertrophic cardiomyopathy 15 • Cardiovascular phenotype | Uncertain significance (Jan 04, 2024) | ||
10-73998231-G-A | Dilated cardiomyopathy 1W | Likely benign (May 15, 2022) | ||
10-73998231-G-T | Likely benign (Dec 12, 2017) | |||
10-73998234-C-T | Dilated cardiomyopathy 1W | Likely benign (Jan 17, 2021) | ||
10-73998237-G-A | Dilated cardiomyopathy 1W | Likely benign (Sep 11, 2020) | ||
10-73998238-A-G | not specified | Uncertain significance (Sep 06, 2012) | ||
10-73998239-G-A | Dilated cardiomyopathy 1W • Cardiovascular phenotype | Uncertain significance (Nov 07, 2022) | ||
10-73998243-C-T | Dilated cardiomyopathy 1W • Cardiomyopathy • Cardiovascular phenotype | Conflicting classifications of pathogenicity (Dec 25, 2023) | ||
10-73998252-G-A | Dilated Cardiomyopathy, Dominant • Dilated cardiomyopathy 1W • Cardiovascular phenotype | Conflicting classifications of pathogenicity (Jan 18, 2024) | ||
10-73998257-C-A | Uncertain significance (Jul 14, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
VCL | protein_coding | protein_coding | ENST00000211998 | 22 | 122047 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.0468 | 0.953 | 125689 | 0 | 59 | 125748 | 0.000235 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.71 | 443 | 635 | 0.698 | 0.0000384 | 7375 |
Missense in Polyphen | 222 | 378.75 | 0.58614 | 4409 | ||
Synonymous | 1.46 | 201 | 229 | 0.878 | 0.0000137 | 2288 |
Loss of Function | 5.14 | 14 | 55.2 | 0.254 | 0.00000328 | 638 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000850 | 0.000850 |
Ashkenazi Jewish | 0.000794 | 0.000794 |
East Asian | 0.000218 | 0.000217 |
Finnish | 0.000139 | 0.000139 |
European (Non-Finnish) | 0.000194 | 0.000193 |
Middle Eastern | 0.000218 | 0.000217 |
South Asian | 0.000133 | 0.000131 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Actin filament (F-actin)-binding protein involved in cell-matrix adhesion and cell-cell adhesion. Regulates cell- surface E-cadherin expression and potentiates mechanosensing by the E-cadherin complex. May also play important roles in cell morphology and locomotion. {ECO:0000269|PubMed:20484056}.;
- Disease
- DISEASE: Cardiomyopathy, dilated 1W (CMD1W) [MIM:611407]: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. {ECO:0000269|PubMed:11815424, ECO:0000269|PubMed:16236538}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cardiomyopathy, familial hypertrophic 15 (CMH15) [MIM:613255]: A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. {ECO:0000269|PubMed:16712796}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Focal adhesion - Homo sapiens (human);Adherens junction - Homo sapiens (human);Amoebiasis - Homo sapiens (human);Regulation of actin cytoskeleton - Homo sapiens (human);Bacterial invasion of epithelial cells - Homo sapiens (human);Shigellosis - Homo sapiens (human);Leukocyte transendothelial migration - Homo sapiens (human);Integrin-mediated Cell Adhesion;Primary Focal Segmental Glomerulosclerosis FSGS;Focal Adhesion;VEGFA-VEGFR2 Signaling Pathway;Regulation of Actin Cytoskeleton;Smooth Muscle Contraction;MAP2K and MAPK activation;Neutrophil degranulation;Disease;Signal Transduction;erk and pi-3 kinase are necessary for collagen binding in corneal epithelia;integrin signaling pathway;rho cell motility signaling pathway;Innate Immune System;Immune System;Muscle contraction;Platelet degranulation ;Response to elevated platelet cytosolic Ca2+;Platelet activation, signaling and aggregation;Integrin;EGFR1;Hemostasis;RAF/MAP kinase cascade;MAPK1/MAPK3 signaling;MAPK family signaling cascades;Signaling by RAS mutants;Signaling by high-kinase activity BRAF mutants;Signaling by moderate kinase activity BRAF mutants;Paradoxical activation of RAF signaling by kinase inactive BRAF;Stabilization and expansion of the E-cadherin adherens junction;Signaling by BRAF and RAF fusions;Oncogenic MAPK signaling;Diseases of signal transduction;Signaling events mediated by focal adhesion kinase;Signaling events mediated by VEGFR1 and VEGFR2;Integrins in angiogenesis;RhoA signaling pathway
(Consensus)
Intolerance Scores
- loftool
- 0.602
- rvis_EVS
- -1.79
- rvis_percentile_EVS
- 2.23
Haploinsufficiency Scores
- pHI
- 0.845
- hipred
- Y
- hipred_score
- 0.639
- ghis
- 0.605
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- H
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.912
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Vcl
- Phenotype
- digestive/alimentary phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); limbs/digits/tail phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); embryo phenotype; cellular phenotype; muscle phenotype; craniofacial phenotype; growth/size/body region phenotype;
Zebrafish Information Network
- Gene name
- vclb
- Affected structure
- fibroblast
- Phenotype tag
- abnormal
- Phenotype quality
- accumulation
Gene ontology
- Biological process
- morphogenesis of an epithelium;platelet degranulation;muscle contraction;cell adhesion;cell-matrix adhesion;lamellipodium assembly;negative regulation of cell migration;adherens junction assembly;protein localization to cell surface;apical junction assembly;neutrophil degranulation;axon extension;platelet aggregation;epithelial cell-cell adhesion
- Cellular component
- podosome;extracellular region;cytosol;cytoskeleton;cell-cell junction;adherens junction;cell-cell adherens junction;fascia adherens;focal adhesion;cell-substrate junction;protein-containing complex;secretory granule lumen;specific granule lumen;sarcolemma;costamere;extracellular exosome;extracellular vesicle;ficolin-1-rich granule lumen
- Molecular function
- dystroglycan binding;actin binding;structural molecule activity;protein binding;beta-catenin binding;ubiquitin protein ligase binding;alpha-catenin binding;cadherin binding